MeSH D012120 - respiration disorders
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D012140:Respiratory tract diseases
D012120:
Respiration disorders
D000532:Altitude sickness
D001049:Apnea
D002639:Cheyne-stokes respiration
0 Companies
0 Drugs
Success rate
D003371:Cough
D004417:Dyspnea
D006685:Hoarseness
0 Companies
0 Drugs
Success rate
D006985:Hyperventilation
0 Companies
0 Drugs
Success rate
D008471:Meconium aspiration syndrome
0 Companies
0 Drugs
Success rate
D009058:Mouth breathing
0 Companies
0 Drugs
Success rate
D012128:Respiratory distress syndrome
D053120:Respiratory aspiration
0 Companies
0 Drugs
Success rate
D056586:Acute chest syndrome
0 Companies
0 Drugs
Success rate
D058088:Sarcoglycanopathies
0 Companies
0 Drugs
Success rate
D059246:Tachypnea
0 Companies
0 Drugs
Success rate
D064706:Vocal cord dysfunction
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Novartis | Naphazoline, Antazoline | Vasocon-a | 1994-07-11 | |||
| Merck & Co | Pseudoephedrine, Azatadine | Trinalin | 1982-03-23 |
1
2
3
4
5
>
Clinical Trials
Historical Success Rate
Phase 1
50%2/4
Phase 2
0%0/5
Phase 3
80%4/5
Approved: 4Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use